A pilot randomized controlled trial of a tailored cognitive behavioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis

BMC Psychiatry

Research Article

Alex Holmes¹  Trevor Kilpatrick²  Jennifer Threader³  Litza A. Kiropoulos⁴ 

[1] Department of Psychiatry, University of Melbourne, Parkville, Victoria, Australia;Melbourne Brain Centre and MS unit, Royal Melbourne Hospital, Parkville, Victoria, Australia;Centre for Neuroscience and the Melbourne Neuroscience Institute, University of Melbourne, Parkville, Victoria, Australia;Florey Neuroscience Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia;Melbourne School of Psychological Sciences, University of Melbourne, 3010, Victoria, Australia;Melbourne School of Psychological Sciences, University of Melbourne, 3010, Victoria, Australia;Psychology Department, Royal Melbourne Hospital, Parkville, Victoria, Australia;

关键词: Depression;    Cognitive behavioral therapy (CBT);    Multiple sclerosis;    Newly diagnosed;    Early intervention;    Anxiety;   

DOI  :  10.1186/s12888-016-1152-7

 received in 2016-05-24, accepted in 2016-12-01,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundTo examine the effectiveness and acceptability of an 8-week individual tailored cognitive behavioural therapy (CBT) intervention for the treatment of depressive symptoms in those newly diagnosed with multiple sclerosis.MethodsThe current study presents a pilot, parallel group randomized controlled trial (RCT) with an allocation ratio of 1:1 conducted in a large research and teaching hospital in Melbourne, Australia. 30 individuals with a mean age of 36.93 years (SD = 9.63) who were newly diagnosed with multiple sclerosis (MS) (X = 24.87 months, SD = 15.61) were randomized to the CBT intervention (n = 15) or treatment as usual (TAU) (n = 15). The primary outcome was level of depressive symptoms using the Beck Depression Inventory-II (BDI-II). Secondary outcomes were level of anxiety, fatigue and pain impact, sleep quality, coping, acceptance of MS illness, MS related quality of life, social support, and resilience. Tertiary outcomes were acceptability and adherence to the intervention.ResultsLarge between group treatment effects were found for level of depressive symptoms at post and at 20 weeks follow-up (d = 1.66–1.34). There were also small to large group treatment effects for level of anxiety, fatigue and pain impact, sleep quality, MS related quality of life, resilience, and social support at post and at 20 weeks follow-up (d = 0.17–1.63). There were no drop-outs and participants completed all treatment modules. All participants reported the treatment as ‘very useful’, and most (73.4%) reported that the intervention had addressed their problems ‘completely’.ConclusionsThese data suggest that the tailored early intervention is appropriate and clinically effective for the treatment of depressive symptoms in those newly diagnosed with MS. A larger RCT comparing the CBT intervention with an active comparative treatment with longer term follow-up and cost effectiveness analyses is warranted. The pilot trial has been retrospectively registered on 28/04/2016 with the ISRCTN registry (trial ID ISRCTN10423371).

【 授权许可】

CC BY   
© The Author(s). 2016